Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1126459

registered interest
date	14/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	254164
answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 10:45:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1123519

registered interest
date	29/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	248610
answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 248611 question first answered 08/05/2019 13:57:42 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1123520

registered interest
date	29/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, who he will be engaging with in the process evaluation on prescribing cannabis-based products for medical use.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	248611
answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 248610 question first answered 08/05/2019 13:57:42 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1123521

registered interest
date	29/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	248612
answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>To stimulate research proposals, the National Institute for Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the United Kingdom market.</p><p>The NIHR also remain open to the submission of proposals outside of these specific calls. Proposals made to NIHR are assessed for scientific rigour, which will include the design of the trials, before funding is allocated to the applicants.</p><p>The process for selecting people for inclusion in any trials will be determined by the researchers and will be dependent on the study design used in the trial.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/05/2019 13:59:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1123443

registered interest
date	26/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	247998
answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 247999 question first answered 07/05/2019 16:43:13 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1123444

registered interest
date	26/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, who will be responsible for offering patients a second opinion on prescribing medical cannabis oil.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	247999
answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 247998 question first answered 07/05/2019 16:43:13 answering member 4455 label Biography information for Seema Kennedy
tabling member	1528 label Biography information for Sir Mike Penning

1039010

registered interest
date	10/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptons have been issued for patients to use medical cannabis since 1 November 2018.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	207185
answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medicinal cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 207187 207189 question first answered 18/01/2019 12:14:21 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

1039016

registered interest
date	10/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions have been honoured at a pharmacy for patients to use medical cannabis since 1 November 2018.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	207187
answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medicinal cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 207185 207189 question first answered 18/01/2019 12:14:21 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

1039029

registered interest
date	10/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of (a) prescriptions issued and (b) patients that use medical cannabis in the next 12 months.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	207189
answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.</p><p> </p><p>The Department has made no estimate of future demand for medicinal cannabis over the next 12 months.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 207185 207187 question first answered 18/01/2019 12:14:21 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

1039035

registered interest
date	10/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions (a) he, (b) Ministers in his Department and (c) officials in his Department with NHS Trusts on implementing adequate measures to ensure access to medical cannabis for patients.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	207190
answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Officials in the Department have worked with colleagues in NHS England, the Medicines and Healthcare products Regulatory Agency, the Home Office and individual National Health Service trusts, as necessary, to ensure that individual patients can access cannabis-based medicinal products where specialist doctors have decided this would be clinically beneficial.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:12:16 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning